Capsigen Inc

Capsigen Inc., based in Vancouver, WA, is at the forefront of capsid engineering, specializing in the transformation of gene therapy delivery through the development of customized adeno-associated virus (AAV) capsids. By leveraging advanced methodologies in biology, directed evolution, and data science, the company aims to create targeted therapies for difficult-to-treat diseases efficiently and effectively.

With a proprietary screening platform known as TRADE, Capsigen is capable of identifying and evolving capsids that meet complex disease-specific profiles, significantly enhancing the potency and specificity of gene therapies. The company's commitment to rapid development processes allows for the delivery of fit-for-purpose capsids typically within a year, positioning Capsigen as a leader in next-generation gene therapy solutions.

Generated from the website